Introduction
Globally, men who have sex with men (MSM) have the highest prevalence of human papillomavirus (HPV), high-grade anal dysplasia (pre-cancer) and anal squamous cell cancer (ASSC), compared with other risk groups [1] . The presence of high-risk (HR) HPV (types 16 and 18) in particular is closely associated with the progression from low-grade squamous intraepithelial lesions (LSIL) to high-grade SIL (HSIL) and also with ASSC [2] [3] [4] . This prevalence and incidence is more common in MSM infected with HIV [2, 5] . In particular, there is an increased prevalence of HPV infections among MSM living with HIV, with a 35.4% pooled HPV 16 prevalence and anal cancer incidence of 45.9 per 100,000 HIV-infected men, as estimated by a recent meta-analysis [4] . Comparatively, in that same metaanalysis, HPV 16 prevalence was estimated to be 12.5% in HIV-uninfected men, with an anal cancer incidence of 5.1 per 100,000 men [4] . Evidence also suggests increased risk for HIV acquisition during infection with oncogenic HPV and persistent HPV infection is more common among men living with HIV compared with uninfected men [6] .
Most epidemiological data on HPV in MSM is from North America, western Europe, and Oceania [4] . While recent epidemiological investigations have demonstrated high-risk sexual behaviours and up to 15% HIV prevalence among Moscow-based MSM, substantially higher than the 1% prevalence in the general adult population, HPV infection has not been a focus of research or public health surveillance among MSM in the Russian Federation [7] [8] [9] [10] [11] . Currently, estimates of the proportion of anal cancers that may be attributable to HPV in eastern Europe and central Asia are currently unavailable. Other modelling estimates from the Statistical Office of the European Union (Eurostat), however, suggest that of 72,694 new cancer cases each year among European men, 17,403 of these could be attributable to HPV and 15,497 attributable to highrisk HPV genotypes [12] . Approximately 30% of all new annual European cancer cases attributable to HPV16/18 are estimated to occur in men [12] .
In light of the lack of information on anal HPV infection among MSM and potential co-infection among those living with HIV in the Russian Federation, this study aimed to explore the existence of anal HPV infection among HIV seronegative and seropositive MSM as well as correlates of infection with oncogenic HPV genotypes 16 and/or 18. Nested within a large epidemiological study of HIV among MSM in Moscow, circulating anal HPV genotypes, anal dysplasia, and other sexually transmitted infections (STIs) among HIV seropositive and seronegative MSM were evaluated.
Methods

Study population and site
Between January 2012 and January 2013, HIV seropositive and seronegative men (n=124) were enrolled from a pool of participants enrolled in a larger cross-sectional study of homosexual, bisexual and other MSM based in Moscow. This parent study also sought to compare the efficiencies of respondent-driven sampling (RDS) and Internet-based sampling (IBS) methods for recruiting MSM for HIV testing and counselling. Eligibility criteria for the parent study included adult men (age > 18 years) who reported anal sex with another man in the last 12 months.
Parent study participants were sampled via RDS and IBS, surveyed, and completed rapid HIV and syphilis testing. Briefly, RDS is a chain recruitment method often used to achieve representative samples of hardto-reach populations [13] . Recruitment began with three purposively-selected 'seeds' who were each provided with four study-specific coupons with which to recruit peer MSM from their social network into the study. Seeds were recruited from the pool of MSM who were involved in local HIV prevention programmes or had participated in prior formative research and were selected to represent a range of individual characteristics. Individuals who were recruited by seeds were assessed for eligibility, consented, and enrolled in the study. At completion of study activities, participants were then provided with three study coupons for further recruitment of peers, constituting a new wave of recruitment. This process continued and 31 waves of participants were ultimately enrolled. A full description of traditional RDS methodology can be found elsewhere [14] . RDS was conducted in Moscow between October 2010 and April 2013 while IBS recruitment took place from late October 2010 to November 2012. IBS recruitment was conducted through banner ads posted on dating websites for MSM, including Qguys, Parniplus, and Bluesystems.ru. When clicked, banner ads linked interested viewers to an online consent form and a brief 10-item online quiz to obtain information on sociodemographic characteristics, sexual identity, and sexual practices. No personal identifiers or IP addresses were obtained from participants. Participants who were preliminarily deemed eligible for the full study, based on online quiz responses, were then directed to a study information page. Participants from both IBS and RDS were provided with the study telephone number via webpage or coupon, respectively, and advised to call to schedule an appointment. All procedures from the appointment onward were the same for RDS and IBS participants.
Participants who completed parent study activities, which included an interviewer-administered survey and HIV and syphilis rapid and confirmatory testing, were assessed for eligibility to participate in a nested HPV sub-study. Because the of the small sample size and the primary interest of identifying circulating HPV genotypes, eligibility for the sub-study was limited to those who self-reported inconsistent condom use during receptive anal sex (last 12 months) to ensure that men who are at risk of HPV infection were included in the sub-study. The HPV sub-study targeted enrolment to relatively equal samples of participants by HIV serostatus. Research activities were conducted in a private health clinic that is known to be accepting of MSM and activities were implemented by a local non-governmental organisation, AIDS Infoshare, which has a history of HIV research with key populations. All activities were conducted in the Russian language and all data collection and testing was anonymous. Remuneration for participation in the sub-study was RUB 2,000 (approximately EUR 50).
Survey measures
As part of the parent study, all participants were asked to complete an anonymous, interviewer-administered, structured survey to capture information on demographics, history of HIV and STI prevention and service use; sexual behaviours with men and women, including anal/oral/vaginal sex; number of sexual partners and partner characteristics; transactional sex (purchased or sold); and substance use. Sexual behaviour measures were adapted from the United States Centers for Disease Control and Prevention (CDC)'s National Health Behavior Survey [15] . Participants who reported past diagnosis of HIV infection were asked additional questions about HIV care and treatment. Additional sexual behaviour questions were asked of HPV sub-study participants to determine if any items had been placed in the anal canal within the last 24 hours, such as douching, use of sex toys, and anal sex, that might impair tests or result in indeterminate results. Computerbased surveys were administered by trained AIDS Infoshare interviewers and time for survey completion ranged from 60 to 90 minutes.
Biological sampling and testing
MSM were tested for HIV and syphilis infection within the parent study; these procedures have been described elsewhere [7] . Briefly, syphilis infection was measured with Lues rapid plasma reaction (RPR) (Nearmedic Plus, Moscow, Russia) and those samples testing positive for syphilis were confirmed with Lues RPGA test (Nearmedic Plus, Moscow, Russia). HIV testing used Determine HIV-1/2 test (Abbott Laboratories, Abbott Park, IL, US) rapid tests. Samples from those testing positive were sent to the local reference laboratory for confirmatory testing. The clinic staff physician provided pre-and post-test HIV counselling and followed all federal protocols [16] . For the purposes of the HPV study, participants are defined as HIV seropositive or seronegative, based on confirmatory study results.
Participants of the HPV sub-study provided additional biological specimens for testing for urethral, oral, and rectal gonorrhoea and chlamydia, as well as for anal cytology and anal HPV genotyping. All specimens for the sub-study were collected by the same study physician and transferred daily for laboratory analysis by a local reference laboratory (Lages Laboratory, Moscow, Russia).
Anorectal specimens were first collected for anal cytology (Papanicolaou (Pap) test) to detect HPV-associated anal dysplasia and followed by anorectal specimen collection for HPV genotyping. Both specimens were collected by inserting a saline-moistened polyester swab into the anal canal into the rectum to ensure sampling of the anorectal transition zone. The swab was rotated slowly during withdraw to capture cells. HPV testing of swabbed cellular material was conducted at the reference laboratory using PCR for amplification of a fragment of the L1 gene to detect the following HPV genotypes: 6, 11, 16, 18, 31, and 33.
Rectal specimens to test for gonococcal and chlamydial infection were then collected by polyester swab inserted at least 2 inches beyond the anal margin and withdrawn in a rotating motion. Participants had the option to provide urethral swabs or urine specimen collection to test for urethral gonococcal and chlamydial infection. The local reference laboratory analysed swabs and urine specimens for gonococcal and chlamydial infection using nucleic acid amplification tests (DiaGen, Moscow, Russia).
All tests, except those for HPV, were performed within 2-3 days of collection, so that participants could be informed of their test results and provided with treatment according to national treatment standards for genital warts, gonorrhoea, syphilis, and chlamydia. Treatment was provided by the study clinic. Participants who screened positive for anal dysplasia by cytology were provided with referrals to the Institute of Proctology in Moscow, where the participant could receive specialised care. Participants with HPV infection, with exception of those with HPV-related genital warts, were not informed of HPV test results as testing was conducted in batches and no treatment was available for men.
Statistical analysis
Descriptive analyses were conducted to estimate the distribution of HPV genotypes, STIs, behavioural characteristics, sexual health history, and use of antiretroviral therapy (ART 
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The study was conducted in partnership with a local non-governmental organisation, AIDS Infoshare, and approved by both the HPV genotypes among HIV seropositive MSM demonstrated slightly different patterns and prevalence compared with HIV seronegative men. Among the total sample, prevalence of HSIL was 11.7%, with no difference by HIV serostatus (p=0.81). Steady partner was defined as 'another man whom you consider to be your boyfriend or partner, to whom you are most committed. ' MSM with HPV 16/18 infection (57.1%; 16/28) reported the use of a condom-incompatible lubricant or no lubricant (incompatible lubricants are those which are not water-or silicon-based, including oils and lotions), which was marginally higher than those without infection (36/93; 38.7%; p=0.08). HSIL (p=0.02) and rectal infection with Chlamydia trachomatis (p=0.02) were associated with HPV 16/18 infection HSIL was present among 24.1% (7/29) of participants with HPV 16/18 infection, compared with 7.6% of those without HPV16/18 (7/92; p=0.02). In the sensitivity analysis (data not shown) with a comparison group of those without any HPV infection, patterns of association were similar to those in Table 3 . Table 4 
Discussion
HPV, particularly its oncogenic genotypes, is prevalent among this sample of Moscow-based MSM and more common among those living with HIV infection. All tested genotypes were detected among the total sample, with 41.2% infected with at least one HPV genotype, the majority of which were comprised of HPV 16 or 18 genotypes. To a lesser degree, HSIL was also identified among this sample. HPV 16/18 infection was significantly or marginally associated with structural factors, sexual behaviours, and individual biological factors. In this context, HIV infection may act as a biological factor for HPV infection, as well as serving as a marker for sexual risk. While rectal C. trachomatis infection was not significant after inclusion in the full model, the magnitude of the odds ratios suggests that such infections may be related to HPV 16/18, which is consistent with studies in other settings [17] . These data represent the first data on HPV and anal dysplasia in MSM from the Russian Federation, as well as the wider EECA Region.
Consistent with other research of HPV in MSM, HPV 16/18 was associated with individual sexual behaviours [3, 18] . In this study, HPV was specifically associated with higher numbers of steady male sexual partners in the last 12 months. While there was no difference across the total numbers of sex partners within the last 12 months, the association with the number of steady partners may actually reflect the sexual relationships where condoms are most inconsistently used, given that condoms tend to be used more consistently during relationships with new partners [9, 19] . Additionally, increased numbers of steady partners among MSM with HPV 16/18 infection may reflect more transient relationships and greater risk behaviour among this subgroup. HPV 16/18 was also associated with regular use of lubricants that are incompatible with latex condoms. Oil-based lubricants or other methods of lubrication (such as body lotion) have been shown to degrade latex condoms during use, potentially facilitating exposure to HPV infection during anal intercourse [20] . Simple interventions that improve condom use with all sexual partners and increase use of condomcompatible lubricants may reduce HPV transmission, as well as HIV and other STIs.
Several structural factors were marginally associated with HPV 16/18. These factors included history of detention in prison and migration to or within the Russian Federation. These may be markers of exposures to new networks in which HPV and/or HIV may be prevalent (e.g. among MSM networks in prison or in a new city) or may reflect low access to prevention methods for HIV/STI [9, 21] . In the absence of data on HPV in Russia or EECA, understanding of HPV transmission related to these structural factors may be derived from research on HIV and other STI. An Internet survey conducted among MSM in 38 European countries in 2010 found that around 65% of Russian men had received information about how STIs can be transmitted during same-sex practices and only 50% had accessed HIV prevention programmes. These indicators for information and access to HIV prevention were below the median estimates for their European counterparts [22] . For those detained in prison/detention or who are new migrants, access to information and prevention methods may be even more limited [23] . Condoms and other HIV prevention methods are not available within prisons or detention facilities in Russia, despite evidence of exposure opportunities and transmission within prisons in Russia and wider EECA countries [24, 25] . During detention, HIV, HPV and other STI transmission may occur through consensual same sex behaviours, rape or other non-consensual practices, and HIV exposure through shared syringes among those who inject drugs [24] . Outside of prison or detention, access to public healthcare is limited by the propiska-like system that requires individuals to be registered and hold documentation for their city of residence. For migrant populations, including internal migrants, this limits access basic HIV and STI prevention [23, 26] . In other European countries, migration status has been associated with increased prevalence of HIV and STI infection [27] .
Findings should be viewed in light of several limitations. First, this was a small, cross-sectional study to explore circulating HPV and oncogenic HPV genotypes among MSM in Moscow, Russia; thus, this small sample size limits statistical power and broader inferences. Selection on the basis of HIV status and self-reported inconsistent condom use may bias the estimates of HPV prevalence. Consistent with other socio-behavioural surveys, additional bias may be introduced with the length of the survey and/or selection bias associated with presenting to the study clinic for participation and participant incentives. As such, these data are not intended to provide prevalence estimates for the country or Moscow city, but provide insight into anal HPV infection among Moscow-based MSM and circulating genotypes. Findings from the multivariable analysis are informative for future research, but the generalisability may be limited by the small sample and non-random sampling method and should be interpreted with caution. Studies with larger samples and prospective analyses are needed to fully understand correlates or predictors of HPV infection among Russian MSM. Data were not collected on smoking duration or dose, which is a known risk factor for progression to HSIL and is relevant in Russia where smoking remains very common [3] . As this was a cross-sectional study, longitudinal data on anal clearance rate of the different HPV types or persistence of infection were not collected and further research is warranted, as persistence has been significantly greater for persons living with HIV, compared with those who are uninfected [6, 18] .
Interventions to reduce HPV transmission among MSM in the Russian Federation are warranted. Both the quadrivalent and bivalent vaccines have demonstrated efficacy against oncogenic HPV-vaccine-type infections in MSM and other men [28] . Modelling estimates have taken such findings further and estimated an 86% reduction in HPV 16/18-related carcinomas among men in Europe with implementation of vaccination of girls and boys vs screening alone [29] . Relative to a female-only programme, vaccination of both genders has demonstrated a greater reduction in male and female HPV-related carcinomas [29] . The quadrivalent HPV vaccine has been licensed for use in Russia and is being tested in school-based, pilot programmes for adolescent girls in four Russian cities, including Moscow, though regional experts have recommended inclusion of boys in vaccination campaigns [30, 31] . While HIV prevention programmes for MSM in the Russian Federation are limited by stigmatization and laws ban 'homosexual propaganda', equitable HPV vaccination programmes for young men and women in the country may impart benefit without requiring disclosure of sexual preferences [32, 33] . Research from North American settings also support the use of anal Pap screening among MSM as an acceptable means of secondary prevention, though cost-effectiveness analyses have yielded mixed results [34, 35] .
Prevention of HPV infection among MSM in the Russian Federation -and ultimately prevention of HSIL -may rely on basic tenets of HIV prevention: condom distribution and ART treatment for those living with HIV. Enabling access to and encouraging use of appropriate condoms and compatible lubricants with all partners during anal intercourse provides protective barriers against HPV acquisition in the absence of other HPV prevention methods. Given that ART has also demonstrated protective benefits against oncogenic HPV, in addition to preventing onward transmission of HIV, HIV testing and access to ART care for MSM who are living with HIV remain critical [36, 37] . As resources for HIV prevention among key populations in the Russian Federation become limited, programmes that are comprehensive and address multiple STIs, including HIV and HPV, and facilitate engagement with HIV care, may be most efficient and promising for protecting health of Russian MSM.
* Erratum:
The title of Table 4 was corrected on 28 April 2015.
